Vidarabine

Vidarabine

SCHEMBL110914

Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADORA1ADORA2AADORA2BADORA3

The experimentally established mechanism targets of Vidarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 known ✓ P0DMS8 4/20 1.00
ADORA2A known ✓ P29274 1/20 1.00
ADORA2B known ✓ P29275 1/20 1.00
ADORA1 known ✓ P30542 1/20 1.00
DPP4 P27487 1/20 1.00
MEN1 O00255 1/20 1.00
SLC28A1 O00337 1/20 1.00
MAP3K7 O43318 1/20 1.00
SLC28A2 O43868 1/20 1.00
GAPDH P04406 1/20 1.00
MAPK1 P28482 1/20 1.00
STAT6 P42226 1/20 1.00
PI4KA P42356 1/20 1.00
KMT2A Q03164 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
PI4K2B Q8TCG2 1/20 1.00
DOT1L Q8TEK3 1/20 1.00
SLC29A1 Q99808 1/20 1.00
PI4K2A Q9BTU6 1/20 1.00
SLC28A3 Q9HAS3 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Adenosine SCHEMBL12352425 1.00 ADORA3 (1.00) ADORA3DPP4MEN1SLC28A1MAP3K7
Adenosine SCHEMBL1821276 1.00 ADORA3 (1.00) ADORA3DPP4MEN1SLC28A1MAP3K7
Adenosine SCHEMBL4522263 1.00 ADORA3 (1.00) ADORA3DPP4MEN1SLC28A1MAP3K7
Adenosine SCHEMBL13362239 1.00 ADORA3 (1.00) ADORA3DPP4MEN1SLC28A1MAP3K7
Adenosine SCHEMBL24538665 1.00 ADORA3 (1.00) ADORA3DPP4MEN1SLC28A1MAP3K7
Adenosine SCHEMBL2228590 1.00 ADORA3 (1.00) ADORA3DPP4MEN1SLC28A1MAP3K7
Adenosine SCHEMBL23804425 1.00 ADORA3 (1.00) ADORA3DPP4MEN1SLC28A1MAP3K7
Adenosine SCHEMBL406207 1.00 ADORA3 (1.00) ADORA3DPP4MEN1SLC28A1MAP3K7
Adenosine SCHEMBL23420216 1.00 ADORA3 (1.00) ADORA3DPP4MEN1SLC28A1MAP3K7
Adenosine SCHEMBL2403819 1.00 ADORA3 (1.00) ADORA3DPP4MEN1SLC28A1MAP3K7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 6502 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4398920-A1 USE OF BACILLUS AMYLOLIQUEFACIENS FOR PREVENTING AND TREATING PARKINSON'S DISEASE Artugen Therapeutics Ltd. (IE) 2024-07-17 EP claimed
CN-112533923-B Pyrazolopyrimidine compounds as adenosine receptor antagonists 爱克思科技有限公司 2024-07-09 CN claimed
US-20240190909-A1 SOLID FORMS OF (2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(((4AR,10AR)-7-HYDROXY-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO[G]QUINOLIN-6-YL)OXY)TETRAHYDRO-2H-PYRAN-2-CARBOXYLIC ACID H. LUNDBECK A/S (DK) 2024-06-13 US claimed
US-20240165081-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INSOMNIA HOFFMAN ABRAHAM J (US) 2024-05-23 US claimed
CN-118019543-A Use of bacillus amyloliquefaciens for preventing and treating parkinson's disease 阿尔图根治疗有限公司 2024-05-10 CN claimed
US-20240108624-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONISTS EXSCIENTIA LTD., (GB) 2024-04-04 US claimed
CN-117729937-A Methods and compositions relating to adenosine receptors 特韦斯特生物科学公司 2024-03-19 CN claimed
CN-117653649-A Novel catecholamine prodrugs for the treatment of parkinson's disease H.隆德贝克有限公司 2024-03-08 CN claimed
CN-117625724-A Drug screening method taking gap connection function as target 中国医学科学院药物研究所 2024-03-01 CN claimed
CN-117599073-A Novel catecholamine prodrugs for the treatment of parkinson's disease H.隆德贝克有限公司 2024-02-27 CN claimed
WO-1989012380-A2 THERAPEUTIC USES OF 2',5'-OLIGOADENYLATE DERIVATIVES TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HI (US) 1989-12-28 WO claimed
EP-0317728-A2 Use of 9-(beta-D-arabinofuranosyl) adenine derivatives for the preparation of pharmaceutical compositions for the treatment of aids WARNER-LAMBERT COMPANY (US) 1989-05-31 EP claimed
EP-0156524-B1 2'-CHLOROPENTOSTATIN, A PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND AND A NOVEL MICROORGANISM FOR PRODUCING THE COMPOUND WARNER-LAMBERT COMPANY (US) 1988-05-11 EP claimed
US-4713372-A 2-chloropentostatin compound having adenosine diaminase inhibitory activity WARNER-LAMBERT COMPANY (US) 1987-12-15 US claimed
EP-0156524-A2 2'-Chloropentostatin, a pharmaceutical composition comprising the compound and a novel microorganism for producing the compound WARNER-LAMBERT COMPANY (US) 1985-10-02 EP claimed
EP-0106309-A2 Biologically active extracts, process for their manufacture, medicinal and cosmetical preparations comprising them, and their use as additives in foodstuffs and stimulants Gauri, Kailash Kumar, Dr. Prof. (DE) 1984-04-25 EP claimed
EP-0079054-A1 Enhancer of antitumor effect Yamasa Shoyu Kabushiki Kaisha (JP) 1983-05-18 EP claimed
US-4315920-A Adenosine deaminase inhibitors BURROUGHS WELLCOME CO. (US) 1982-02-16 US claimed
US-4123609-A PHOSPHORYLATION, HYDROLYSIS WARNER-LAMBERT COMPANY (US) 1978-10-31 US claimed
US-4055717-A 9-(3-O-Acyl-β-D-arabinofuranosyl)adenine compounds, 9-(2,3-di-O-acyl-β-D-arabinofuranosyl)-adenine compounds, and method for their production PARKE, DAVIS & COMPANY (US) 1977-10-25 US claimed